We are live on ! Find out more
DNLI icon

Denali Therapeutics
DNLI

170 hedge funds and large institutions have $2.96B invested in Denali Therapeutics in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 20

48% more capital invested

Capital invested by funds: $2B → $2.96B (+$960M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

15% more funds holding

Funds holding: 148 → 170 (+22)

13% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 48

0.26% less ownership

Funds ownership: 78.36% → 78.09% (-0.26%)

18% less call options, than puts

Call options by funds: $2.08M | Put options by funds: $2.55M

Holders
170
Holders Change
+22
Holders Change %
+14.86%
% of All Funds
3.43%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
42
Increased
54
Reduced
48
Closed
20
Calls
$2.08M
Puts
$2.55M
Net Calls
-$463K
Net Calls Change
-$976K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$52.4M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$46.6M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
+$10.3M
4
Marshall Wace
Marshall Wace
United Kingdom
+$8.63M
5
Goldman Sachs
Goldman Sachs
New York
+$8.36M

Top Sellers

1
FP
Flagship Pioneering
Massachusetts
-$60.2M
2
CM
Crestline Management
Texas
-$43.5M
3
EC
EcoR1 Capital
California
-$17.7M
4
CCM
CAAS Capital Management
New York
-$15M
5
MWNA
Marshall Wace North America
New York
-$11.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Zurich Cantonal Bank
126
Zurich Cantonal Bank
Switzerland
$307K – – –
EGM
127
Engineers Gate Manager
New York
$289K +$243K +8,056 New
VF
128
Virtu Financial
New York
$280K +$235K +7,801 New
SC
129
Saturna Capital
Washington
$251K +$211K +7,000 New
Citigroup
130
Citigroup
New York
$249K -$1.29M -42,920 -86%
Stifel Financial
131
Stifel Financial
Missouri
$225K +$189K +6,271 New
UBS Group
132
UBS Group
Switzerland
$224K +$108K +3,570 +133%
QT
133
Quantamental Technologies
New York
$221K +$186K +6,179 New
Canada Life
134
Canada Life
Manitoba, Canada
$216K – – –
ECM
135
ExodusPoint Capital Management
New York
$205K -$299K -9,914 -63%
ASN
136
Advisory Services Network
Georgia
$201K +$169K +5,619 New
AIP
137
Ameritas Investment Partners
Nebraska
$199K – – –
Macquarie Group
138
Macquarie Group
Australia
$137K – – –
Bank of Montreal
139
Bank of Montreal
Ontario, Canada
$111K -$61.6K -2,045 -41%
WLPWM
140
Walled Lake Planning & Wealth Management
Illinois
$107K +$90.3K +3,000 New
QT
141
Quantbot Technologies
New York
$106K +$89.8K +2,981 New
Nisa Investment Advisors
142
Nisa Investment Advisors
Missouri
$93K +$55.1K +1,830 +241%
Rockefeller Capital Management
143
Rockefeller Capital Management
New York
$89K +$75.3K +2,500 New
MAM
144
Meeder Asset Management
Ohio
$88K +$59K +1,960 +421%
TRCT
145
Tower Research Capital (TRC)
New York
$83K -$219K -7,275 -76%
Pacer Advisors
146
Pacer Advisors
Pennsylvania
$67K +$56.3K +1,870 New
FC
147
FORA Capital
Florida
$66K +$55.4K +1,839 New
Royal Bank of Canada
148
Royal Bank of Canada
Ontario, Canada
$57K +$9.34K +310 +24%
HPC
149
HM Payson & Co
Maine
$45K +$37.6K +1,250 New
PNC Financial Services Group
150
PNC Financial Services Group
Pennsylvania
$33K – – –
4 5
6
7 8

DNLI Hedge Fund Activity: Q3 2020 in Review

170 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2020, worth a combined $2.96B — up 48% from $2B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new DNLI positions and 20 closed out — a net gain of 22 holders — while 54 added to existing stakes and 48 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $52.4M. The largest seller was Flagship Pioneering, cutting an estimated $60.2M.

  • 170 institutional investors held Denali Therapeutics (DNLI) as of Q3 2020, up from 148 in Q2 2020.
  • Funds reported $2.96B of Denali Therapeutics stock for Q3 2020, up 48% quarter-over-quarter.
  • 42 funds opened new Denali Therapeutics positions in Q3 2020 and 20 closed out, a net change of +22 holders.
  • The largest Denali Therapeutics buyer in Q3 2020 was T. Rowe Price Associates, an estimated $52.4M added.
  • The largest Denali Therapeutics seller in Q3 2020 was Flagship Pioneering, an estimated $60.2M sold.

Based on aggregated 13F filings for Q3 2020.